According to our findings, EML4-ALK V1, V3a and V3b harboring the F1174S mutation are sensitive, rather than resistant, to crizotinib highlighting the complexity of monitoring and understanding resistance mechanisms in the NSCLC tumor landscape. This evidence concerns the gene ALK and neoplasm.